# Ascendis Pharma A/S (ASND)

Source page: https://stoqly.net/companies/asnd

- **Ticker:** ASND (Nasdaq)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001612042
- **Latest annual report:** 20-F filed 2026-02-11 (https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $251.27 on 2026-10-30
- **Market cap:** $15.2B
- **EPS, trailing 12 months:** −$4.24
- **Revenue (FY2025):** $812M
- **Revenue growth:** +106.4%
- **Revenue growth, 5-year CAGR:** +152.4%
- **Gross margin:** 86.8%
- **Operating margin:** −18.9%
- **Net margin:** −31.7%
- **Net debt:** $122M
- **Change in share count:** +4.7%
- **Piotroski F-score:** 5/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/asnd/figures.csv

| US$ millions | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 5 | 2 | 12 | 15 | 8 | 9 | 54 | 288 | 393 | 812 |
| Operating income | -81 | -126 | -183 | -254 | -377 | -534 | -590 | -493 | -302 | -154 |
| Net income | -76 | -140 | -154 | -244 | -478 | -454 | -613 | -521 | -409 | -257 |
| Diluted EPS (US$) | -2.85 | -4.15 | -3.74 | -5.25 | -9.44 | -8.28 | -10.93 | -9.25 | -7.06 | -4.24 |
| Operating cash flow | -67 | -107 | -164 | -197 | -310 | -494 | -521 | -505 | -331 | 61 |
| Free cash flow | -67 | -108 | -167 | -203 | -332 | -522 | -536 | -508 | — | — |
| Cash | 190 | 234 | 318 | 672 | 717 | 505 | 474 | 433 | 581 | 724 |
| Debt and leases | — | — | — | — | — | 119 | 426 | 603 | 793 | 846 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.